CD274 and gastroesophageal junction adenocarcinoma: The GEMSTONE-303 trial assessed the efficacy and safety of sugemalimab plus capecitabine and oxaliplatin (SUG-CAP) as a first-line treatment for advanced G/GEJ adenocarcinoma with PD-L1 CPS ≥5 (15).